Submitted:
17 March 2025
Posted:
18 March 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction to Drug Delivery Systems
1.1. Evolution from Conventional Tablets to Modern Drug Delivery Techniques
1.2. Importance of Patient Compliance and Therapeutic Effectiveness
2. Chewable Tablets as an Effective Oral Drug Delivery System
2.1. Formulation, Benefits, and Challenges of Chewable Tablets
| Aspect | Description | Key Benefits/Challenges | Reference |
|---|---|---|---|
| Formulation | Uses flavouring agents, sweeteners, and disintegrants | Ensures palatable taste and mouthfeel | [6] |
| Benefits | Bypasses first-pass metabolism in some cases | Improved bioavailability | [6] |
| Challenges | Stability, grittiness, and active ingredient degradation | Requires optimization for patient compliance | [7] |
2.2. Pharmacokinetics and Therapeutic Applications
| Category | Description | Key Benefits/Challenges | Reference |
|---|---|---|---|
| Pharmacokinetics | Influenced by solubility, absorption site, and formulation | Faster onset due to partial oral mucosal absorption | [8] |
| Therapeutic Applications | Used in analgesics, vitamins, and antacids | Convenient, patient-friendly administration | [9] |
3. Targeted Drug Delivery Approaches
3.1. Rationale and Strategies for Targeting Drug Delivery
3.2. Role of Nanotechnology in Improving Drug Targeting
| Category | Description | Key Benefits/Challenges | Reference |
|---|---|---|---|
| Targeted Drug Delivery | Directs drugs to diseased tissues to minimize side effects | Enhances therapeutic efficacy, reduces toxicity | [10] |
| Passive Targeting | Utilizes the EPR effect for nanoparticle accumulation in tumors | Improves drug concentration at tumor sites | [11] |
| Active Targeting | Uses ligands to bind to specific cell receptors | Enhances drug localization and uptake | [11] |
| Nanotechnology in Drug Targeting | Enables precise control over drug release and particle behavior | Ensures site-specific drug action | [12] |
| Theranostic Systems | Combines therapy and imaging for real-time treatment monitoring | Allows personalized and adaptive treatments | [13] |
4. Liposomal and Nanoparticle-Based Delivery Systems
4.1. Liposomes as Vesicular Carriers for Drug Transport
4.2. FDA-Approved Nanomedicines and Their Clinical Significance
5. Innovations in Naso-Pulmonary Drug Delivery
5.1. Advances in Respiratory Health Management
5.2. Role of Nanoparticles in Pulmonary Therapeutics
6. Future Perspectives and Challenges in Drug Delivery
6.1. Theranostics and Image-Guided Drug Administration
| Aspect | Description | Key Challenges |
|---|---|---|
| Targeted Medicine | Personalized drug delivery based on genetic and molecular markers | Regulatory hurdles, cost of development |
| Gene Therapy | Uses genetic modifications to treat diseases | Ethical concerns, precise targeting issues |
| Nanotechnology in Medicine | Enhances drug delivery and bioavailability | Manufacturing complexities, stability concerns |
| Theranostics | Combines therapy and diagnostics for real-time tracking | High development costs, integration with imaging |
| Image-Guided Drug Delivery | Utilizes imaging techniques to improve targeting | Equipment availability, need for specialized expertise |
7. Conclusions
References
- Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. International Journal of Research Publication and Reviews, 4(8), 1379-1384.
- Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. World Journal of Pharmaceutical Research, 13(13), 1155-1169. [CrossRef]
- Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. World Journal of Pharmaceutical Research, 13(13), 1243-1262. [CrossRef]
- Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World Journal of Pharmaceutical Research, 13(13), 1112-1140. [CrossRef]
- Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. World Journal of Pharmaceutical Research, 13(16), 176-189. [CrossRef]
- Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48. [CrossRef]
- Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117-134. [CrossRef]
- Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33(10), 2373-2387. [CrossRef]
- Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chemical Reviews, 116(5), 2826-2885. [CrossRef]
- Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20. [CrossRef]
- Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419-436. [CrossRef]
- Gao, W., Chan, J. M., & Farokhzad, O. C. (2010). pH-responsive nanoparticles for drug delivery. Molecular Pharmaceutics, 7(6), 1913-1920. [CrossRef]
- Koo, H., Huh, M. S., Sun, I. C., Yuk, S. H., Choi, K., Kim, K., & Kwon, I. C. (2011). In vivo targeted delivery of nanoparticles for theranosis. Accounts of Chemical Research, 44(10), 1018-1028. [CrossRef]
- Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012). Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Molecular Pharmaceutics, 7(6), 1899-1912. [CrossRef]
- Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1-2), 271-284. [CrossRef]
- Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: Current status and future prospects. The FASEB Journal, 19(3), 311-330. [CrossRef]
- Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751-760. [CrossRef]
- Petros, R. A., & DeSimone, J. M. (2010). Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 9(8), 615-627. [CrossRef]
- Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20-37. [CrossRef]
- Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145-160. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).